Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human papillomavirus 9-valent vaccine
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Recombinant human papillomavirus 9-valent vaccine is a non-infectious, recombinant vaccine designed to protect against nine types of human papillomavirus (HPV): types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The vaccine is composed of purified virus-like particles (VLPs) formed from the major capsid protein L1 of each HPV type. These VLPs are produced using recombinant Saccharomyces cerevisiae yeast cells and self-assemble to mimic the structure of natural HPV virions without containing viral DNA or causing infection[8][6]. The primary mechanism involves stimulating the immune system to produce neutralizing antibodies that prevent initial infection by binding to the virus and blocking its entry into host cells[1][7]. Gardasil 9 is indicated for prevention of cervical, vulvar, vaginal and anal cancers; cervical adenocarcinoma; precancerous or dysplastic lesions; and genital warts caused by these nine HPV types[6][7]. The developer and manufacturer is Merck Sharp & Dohme LLC.
- Brand names
- Gardasil 9Gardasil9Gardasil-9
- Other names
- Papillomavirus (9-Valent) Vaccine (Human, Recombinant)Human Papillomavirus 9-valent Vaccine, Recombinant
02
Targets
HPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1HPV31 L1Human papillomavirus type 33 L1 major capsid proteinHPV45 L1HPV52 L1 (Human papillomavirus type 52 major capsid protein L1)Human papillomavirus type 58 L1 major capsid proteinHPV6 L1 (Human papillomavirus type 6 major capsid protein L1)HPV L1 (Human papillomavirus L1 capsid protein)
Beyond the preview
Go deeper on recombinant human papillomavirus 9-valent vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human papillomavirus 9-valent vaccine.